You are here: Industry Insights > AstraZeneca

News List

Sierra Oncology licenses myelofibrosis candidate from AstraZeneca pharmatimes
August 09, 2021
Under a new agreement, AstraZeneca will licence AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode, to Sierra Oncology.
FDA to allow export of certain lots of AstraZeneca COVID-19 vaccine made at Baltimore plant firstwordpharma
August 09, 2021
The FDA said certain lots of AstraZeneca's COVID-19 vaccine manufactured at Emergent Biosolutions' Baltimore facility are fit to be shipped outside the US, as reported Financial Post.
Botswana: AstraZeneca Vaccines Arrives in Botswana firstwordpharma
August 09, 2021
Government of Botswana this afternoon received 38 400 doses of the AstraZeneca vaccine.
Combination of the first component of Sputnik V vaccine (Sputnik Light vaccine) with vaccines by AstraZeneca, Sinopharm and Moderna demonstrates high safety profile during the study in Argentina’s Bue firstwordpharma
August 05, 2021
RDIF announces the initial safety results of the randomized, single-blind study for the evaluation of the immune response and safety of heterogeneous regimens combining the first component of the Russian Sputnik V vaccine against coronavirus.
AstraZeneca reveals $15.54 billion in revenues in H1 2021 europeanpharmaceuticalreview
August 04, 2021
H1 financial results show AstraZeneca’s revenues grew by 23 percent in 2021, with $14.37 billion attributed to activities aside from COVID-19 vaccine sales.
Saphnelo Approved in US for Moderate to Severe Systemic Lupus Erythematosus americanpharmaceuticalreview
August 04, 2021
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
AZ’s Saphnelo scores US approval for systemic lupus erythematosus pharmatimes
August 03, 2021
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Saphnelo (anifrolumab) for the treatment of moderate to severe systemic lupus erythematosus (SLE).
AstraZeneca and Sputnik V combination show no adverse events: RFID expresspharma
August 02, 2021
The world’s first study of a combination between the AstraZeneca vaccine and the first component of the Sputnik V vaccine (Sputnik Light) in Azerbaijan shows no serious adverse events or COVID infection cases following the vaccination.
Saudi study documents safety of AstraZeneca firstwordpharma
August 02, 2021
A study from Saudi Arabia found that no major side effects were associated with AstraZeneca's COVID-19 vaccine AZD1222 and no breakthrough infections were seen, Arab News reported.
PM: Cambodians to receive AstraZeneca 3rd dose as 'booster' firstwordpharma
August 02, 2021
Cambodia prime minister Hun Sen said that the country will implement booster doses with COVID-19 vaccines, beginning with frontline workers, Khmer Times reported Sunday.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page